Triple therapy shows promise in advanced liver cancer trial
NCT ID NCT05665348
First seen Mar 11, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested whether adding a third drug, ipilimumab, to a two-drug combination (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer or have better tumor shrinkage. 229 participants received either the two-drug or three-drug treatment for up to 2 years, followed by 2 years of monitoring. The goal was to see if the triple therapy improves overall survival and response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAC Eugène Marquis
Rennes, France
-
CAC Gustave Roussy
Villejuif, France
-
CAC Paoli Calmettes
Marseille, France
-
CH HCC
Colmar, France
-
CH Saint-Jean
Perpignan, France
-
CHD Vendée
La Roche-sur-Yon, France
-
CHRU Hôpitaux de Tours
Tours, France
-
CHU
Angers, France
-
CHU Hôtel Dieu
Nantes, France
-
CHU Robert Debré
Reims, France
-
Cac Icans
Strasbourg, France
-
Centre Hospitalier
Cholet, France
-
Centre Hospitalier
Pau, France
-
Centre Hospitalier
Quimper, France
-
Centre Hospitalier
St-Malo, France
-
Centre Hospitalier
Valence, France
-
Ch Annecy Genevois
Pringy, France
-
Ch Duchenne
Boulogne-sur-Mer, France
-
Chu Amiens Picardie
Amiens, France
-
Chu Avicienne
Bobigny, France
-
Chu Beaujon
Clichy, France
-
Chu Brabois
Vandœuvre-lès-Nancy, France
-
Chu Charles Nicolle
Rouen, France
-
Chu Dupuytren
Limoges, France
-
Chu Estaing
Clermont-Ferrand, France
-
Chu Francois Mitterand
Dijon, France
-
Chu Haut Leveque
Pessac, France
-
Chu Haut-Leveque
Pessac, France
-
Chu L'Archet
Nice, France
-
Chu La Croix Rousse
Lyon, France
-
Chu La Miletrie
Poitiers, France
-
Chu La Pitie Salpetriere
Paris, France
-
Chu La Timone
Marseille, France
-
Chu Morvan
Brest, France
-
Chu Rangueil
Toulouse, France
-
Chu Saint Antoine
Paris, France
-
Chu Saint-Eloi
Montpellier, France
-
Chu Saint-Etienne
Saint-Priest-en-Jarez, France
-
Privé Bordeaux Nord
Bordeaux, France
-
Privé CONFLUENT
Nantes, France
-
Privé HPCA
Plérin, France
-
Privé LES BONNETTES
Arras, France
-
Privé Saint-Joseph
Marseille, France
-
Privé Saint-Joseph
Paris, France
-
Privé Sainte Anne
Strasbourg, France
Conditions
Explore the condition pages connected to this study.